Mar 26 |
30 Countries with the Lowest Depression Rates
|
Mar 26 |
20 Cloudiest Cities in the U.S., Ranked
|
Mar 25 |
What's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday?
|
Mar 25 |
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
|
Mar 25 |
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
|
Mar 23 |
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
|
Mar 22 |
Axsome Triumphs Over Major Depressive Disorder With Auvelity
|
Mar 20 |
Axsome (AXSM) Begins Dosing in Depression Study on Sunosi
|
Mar 19 |
Baird starts Axsome at outperform, cites upcoming data
|
Mar 19 |
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
|